source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy

Mogrify logo 12.4.19UK-based cell therapy specialist Cell Mogrify Ltd has completed a second close on its seed funding, bringing the total raised to $3.7 million which it will use to market novel IP and cell types generated using its proprietary direct cellular conversion platform designed to power the development and manufacture of lifesaving cell therapies across all therapeutic areas. The funding round was led by existing investor Ahren Innovation Capital, with 24Haymarket and Dr Darrin Disley OBE, its recently appointed CEO, also investing.

Mogrify builds on a ten-year investment by its co-founders in the development of a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors or small molecules needed to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell or a progenitor cell state. The company is applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development and manufacturing, a $30 billion market opportunity that is rapidly growing at an estimated CAGR of more than 30%. In addition, through its internal development and partnership programmes, Mogrify is positioning itself to directly address growing markets that are unserved by approved cell therapies, such as the cardiac repair and cartilage regeneration end-user markets, which are estimated to be worth $120 billion and $7 billion by 2022 and 2025, respectively.

For further information about Cell Mogrify Ltd visit www.mogrify.co.uk

Last modified onFriday, 12 April 2019 08:26

Latest from Tom Mulligan